GGrantIndex
← Leaderboards

John H Eldridge

University Of Alabama At Birmingham

$16,167,741
Attributed
$19,413,925
Total exposure
8
Grants
6
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $3.9M · FY201223
$5M$3.8M$2.5M$1.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$19,413,925 · 8

By mechanism

U19$12,353,270 · 4
R01$5,335,752 · 1
R56$1,156,616 · 1
R43$300,000 · 1
P01$268,287 · 1

Top collaborators

Most similar at University Of Alabama At Birmingham

Same institution · by research overlap

Others in their field

Top investigators on “Vaccines

Research focus

VaccinesVirusUnited States National Institutes Of HealthEbola VirusAreaNational Institute Of Allergy And Infectious DiseaseCenters For Disease Control And Prevention (U.S.)ImmunogenicityDisease OutbreaksSafetyRecombinantsToxicologyCategoriesDoseVesicular Stomatitis Indiana VirusVectorBaseVirus DiseasesLaboratoriesClinical TrialsCyclic GmpAttenuatedVaccine DeliverySeeds

Grant awards (23)

Project 1 - Profectus Biosciences, Inc.$867,787
U19 · FY2023 · AI · contact PI
Research Project 1: Vaccine for Rapid Response to Filovirus Outbreak$874,537
U19 · FY2022 · AI · contact PI
Project 1 - Profectus Biosciences, Inc.$802,301
U19 · FY2022 · AI · contact PI
Research Project 1: Vaccine for Rapid Response to Filovirus Outbreak$963,069
U19 · FY2021 · AI · contact PI
Project 1 - Profectus Biosciences, Inc.$864,462
U19 · FY2021 · AI · contact PI
Project 1 - Profectus Biosciences, Inc.$839,059
U19 · FY2020 · AI · contact PI
Project 1 - Profectus Biosciences, Inc.$805,740
U19 · FY2019 · AI · contact PI
Research Project 1: Vaccine for Rapid Response to Filovirus Outbreak$742,798
U19 · FY2019 · AI · contact PI
RP1: rVSV Vectored Vaccine to Treat Ebola and Marburg Infection$263,375
U19 · FY2018 · AI · contact PI
RP1: rVSV Vectored Vaccine to Treat Ebola and Marburg Infection$244,952
U19 · FY2017 · AI · contact PI
RP1: rVSV Vectored Vaccine to Treat Ebola and Marburg Infection$2,733,163
U19 · FY2016 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,208,817
R01 · FY2016 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$947,203
R01 · FY2015 · AI · contact PI
RP1: rVSV Vectored Vaccine to Treat Ebola and Marburg Infection$797,292
U19 · FY2015 · AI · contact PI
RP1: rVSV Vectored Vaccine to Treat Ebola and Marburg Infection$1,554,735
U19 · FY2014 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$937,397
R01 · FY2014 · AI · contact PI
Development of Chimeric Vesiculo/Alphaviruses as an Alphavirus Vaccine$1,156,616
R56 · FY2013 · AI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,122,164
R01 · FY2013 · AI · contact PI
rVSV Vectored Vaccine to Protect Against Ebola and Marburg Viruses$1,120,171
R01 · FY2012 · AI · contact PI
Prime/Boost Vaccine to Prevent Hepatocellular Carcinoma$300,000
R43 · FY2012 · CA · contact PI
ANTIGEN DELIVERY SYSTEM FOR HIV AND SIV VACCINES$0
P01 · FY2002 · AI
ANTIGEN DELIVERY SYSTEM FOR HIV AND SIV VACCINES$0
P01 · FY2001 · AI
ANTIGEN DELIVERY SYSTEM FOR HIV AND SIV VACCINES$268,287
P01 · FY2000 · AI